BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25069387)

  • 1. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study.
    Lazo-Langner A; Fleet JL; McArthur E; Garg AX
    J Thromb Haemost; 2014 Oct; 12(10):1626-35. PubMed ID: 25069387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study].
    Peidro-Garcés L; Otero-Fernandez R; Lozano-Lizarraga L
    Rev Esp Cir Ortop Traumatol; 2013; 57(1):53-60. PubMed ID: 23594983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
    Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
    J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey.
    Rogers BA; Phillips S; Foote J; Drabu KJ
    Ann R Coll Surg Engl; 2010 Nov; 92(8):668-72. PubMed ID: 20615303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
    Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA
    N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
    Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
    J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.
    Long A; Zhang L; Zhang Y; Jiang B; Mao Z; Li H; Zhang S; Xie Z; Tang P
    J Thromb Thrombolysis; 2014 Oct; 38(3):299-305. PubMed ID: 24402194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
    Turpie AG; Schmidt AC; Kreutz R; Lassen MR; Jamal W; Mantovani L; Haas S
    Vasc Health Risk Manag; 2012; 8():363-70. PubMed ID: 22701330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
    Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
    Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
    J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
    Senay A; Trottier M; Delisle J; Banica A; Benoit B; Laflamme GY; Malo M; Nguyen H; Ranger P; Fernandes JC
    Vasc Health Risk Manag; 2018; 14():81-89. PubMed ID: 29780248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study.
    Loganathan V; Hua A; Patel S; Gibbons C; Vizcaychipi MP
    Ann R Coll Surg Engl; 2016 Sep; 98(7):507-15. PubMed ID: 27580310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis.
    Kapoor A; Ellis A; Shaffer N; Gurwitz J; Chandramohan A; Saulino J; Ishak A; Okubanjo T; Michota F; Hylek E; Trikalinos TA
    J Thromb Haemost; 2017 Feb; 15(2):284-294. PubMed ID: 28102615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
    Eriksson BI; Kakkar AK; Turpie AG; Gent M; Bandel TJ; Homering M; Misselwitz F; Lassen MR
    J Bone Joint Surg Br; 2009 May; 91(5):636-44. PubMed ID: 19407299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis.
    Neumann I; Rada G; Claro JC; Carrasco-Labra A; Thorlund K; Akl EA; Bates SM; Guyatt GH
    Ann Intern Med; 2012 May; 156(10):710-9. PubMed ID: 22412038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.